Novo Nordisk's shares plummet more than 16% after results of new drug
Novo Nordisk's shares sharply declined following disappointing clinical trial results of its new weight-loss drug, CagriSema, which underperformed compared to a competitor's product.
Wegovy and Ozempic owner dealt blow as next-gen weight-loss drug is branded ‘obsolete’
Novo Nordisk's new weight-loss drug, CagriSema, has been deemed 'obsolete' after disappointing clinical trials, leading to a significant drop in the company's shares.
Novo Nordisk: 15% Drop in Stock - Why the Clinical Trial of CagriSema Was Disappointing
Novo Nordisk's stock plummeted 15% after its new drug CagriSema failed to meet key weight-loss targets in a clinical trial compared to Eli Lilly's tirzepatide.
Novo Nordisk sinks again on the stock market after failing trials for its new obesity drug
Novo Nordisk's shares dropped significantly after the company reported failures in trials for its experimental obesity drug, CagriSema.
Novo Nordisk Stock Falls After New Data on Weight Loss Hope
Novo Nordisk's stock drops following the release of new study data on the company's weight loss drug, Cagrisema, which showed a 23% weight loss over 84 weeks.
Novo Nordisk stock closes at lowest price since 2021
Novo Nordisk's stock dropped over 16%, closing at its lowest since June 2021, following disappointing results from a weight-loss study.